Emerging as a noteworthy breakthrough in the battle against obesity, Retatrutide is generating considerable buzz. This treatment combines the action of two established GLP-1 binding agonists, dulaglutide , with an unique glucose-dependent peptide component. Preliminary study results have indicated significant weight loss in patients with a high BMI